Vaxcyte, Inc. PCVX
We take great care to ensure that the data presented and summarized in this overview for Vaxcyte, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PCVX
View all-
Janus Henderson Group PLC London, X013.1MShares$633 Million0.23% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.3MShares$596 Million0.01% of portfolio
-
Ra Capital Management, L.P. Boston, MA12MShares$578 Million7.4% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$480 Million0.02% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD8.32MShares$402 Million0.18% of portfolio
-
Wellington Management Group LLP Boston, MA5.03MShares$243 Million0.03% of portfolio
-
State Street Corp Boston, MA4.79MShares$231 Million0.01% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY4.29MShares$207 Million0.1% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY3.78MShares$183 Million4.39% of portfolio
-
Westfield Capital Management CO LP Boston, MA3.73MShares$180 Million0.61% of portfolio
Latest Institutional Activity in PCVX
Top Purchases
Top Sells
About PCVX
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Insider Transactions at PCVX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 15
2026
|
Olivier Brandicourt Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,357
+35.14%
|
-
|
|
Jan 14
2026
|
Andrew Guggenhime PRESIDENT AND CFO |
BUY
Bona fide gift
|
Indirect |
61,850
+50.0%
|
-
|
|
Jan 14
2026
|
Andrew Guggenhime PRESIDENT AND CFO |
SELL
Bona fide gift
|
Direct |
61,850
-49.76%
|
-
|
|
Jan 14
2026
|
Grant Pickering CHIEF EXECUTIVE OFFICER |
SELL
Bona fide gift
|
Direct |
100,000
-19.96%
|
-
|
|
Dec 31
2025
|
Harpreet S. Dhaliwal Chief Technical Ops Officer |
SELL
Open market or private sale
|
Direct |
9,743
-28.94%
|
$448,178
$46.69 P/Share
|
|
Dec 23
2025
|
Elvia Cowan SVP, FINANCE |
SELL
Bona fide gift
|
Direct |
1,000
-6.88%
|
-
|
|
Dec 23
2025
|
Elvia Cowan SVP, FINANCE |
SELL
Open market or private sale
|
Direct |
11,623
-25.18%
|
$546,281
$47.92 P/Share
|
|
Sep 08
2025
|
Grant Pickering CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
7,356
-1.45%
|
$235,392
$32.41 P/Share
|
|
Sep 08
2025
|
Andrew Guggenhime PRESIDENT AND CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,890
-2.27%
|
$92,480
$32.41 P/Share
|
|
Sep 08
2025
|
Jim Wassil CHIEF OPERATING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
2,759
-1.91%
|
$88,288
$32.41 P/Share
|
|
Sep 08
2025
|
Harpreet S. Dhaliwal Chief Technical Ops Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,204
-3.45%
|
$38,528
$32.41 P/Share
|
|
Sep 08
2025
|
Elvia Cowan SVP, FINANCE |
SELL
Payment of exercise price or tax liability
|
Direct |
482
-1.81%
|
$15,424
$32.41 P/Share
|
|
Sep 07
2025
|
Elvia Cowan SVP, FINANCE |
BUY
Grant, award, or other acquisition
|
Direct |
2,810
+9.36%
|
-
|
|
Sep 02
2025
|
Grant Pickering CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
10,840
-0.7%
|
$336,040
$31.56 P/Share
|
|
Sep 02
2025
|
Andrew Guggenhime PRESIDENT AND CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,080
-1.3%
|
$157,480
$31.56 P/Share
|
|
Sep 02
2025
|
Jim Wassil CHIEF OPERATING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
4,286
-0.96%
|
$132,866
$31.56 P/Share
|
|
Sep 02
2025
|
Harpreet S. Dhaliwal Chief Technical Ops Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,538
-1.43%
|
$47,678
$31.56 P/Share
|
|
Sep 02
2025
|
Elvia Cowan SVP, FINANCE |
SELL
Payment of exercise price or tax liability
|
Direct |
567
-1.05%
|
$17,577
$31.56 P/Share
|
|
Jun 12
2025
|
Olivier Brandicourt Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,148
+50.0%
|
-
|
|
Jun 12
2025
|
Teri Loxam Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,041
+22.94%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 155K shares |
|---|---|
| Exercise of conversion of derivative security | 66.3K shares |
| Bona fide gift | 61.9K shares |
| Payment of exercise price or tax liability | 60.9K shares |
|---|---|
| Bona fide gift | 163K shares |
| Open market or private sale | 55.4K shares |